Literature DB >> 21358015

Health-related quality of life in primary antibody deficiency.

Asghar Aghamohammadi1, Ali Montazeri, Hassan Abolhassani, Sepideh Saroukhani, Sarvenaz Pourjabbar, Mahmoud Tavassoli, Behzad Darabi, Amir Imanzadeh, Nima Parvaneh, Nima Rezaei.   

Abstract

Patients with primary antibody deficiencies (PAD) are susceptible to recurrent and chronic infections and a variety of complications. This study was performed to assess quality of life (QoL) of PAD patients who were under long term treatment and regular follow-up.Thirty six adults with proved diagnosis of PAD, who had received regular intravenous immunoglobulin replacement therapy, were enrolled in this study. The QoL of selected PAD patients was measured by Medical Outcomes Study 36-item Short-Form (SF-36) Health Survey questionnaire.The patients with PAD showed significantly reduced scores in physical component in comparison with healthy age-sex matched control subjects (60.2±20.1 vs. 85.5±4.7, P<0.001). Mental component score was also significantly decreased in the patient's group (59.8±19.5 vs. 72.3±3.4, P=0.002). There was a reverse association between SF-36 scores and number of infections episodes (r=-0.73 P=0.003). The patients with long delay diagnosis showed significantly lower SF-36 scores (r=-0.62, P=0.003).The patients with PAD who were diagnosed timely and managed appropriately seem to have lower complications and better QoL. However, the patients with severe phenotypes and long delay in diagnosis showed lower QoL, even in medical management.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21358015     DOI: 010.01/ijaai.4751

Source DB:  PubMed          Journal:  Iran J Allergy Asthma Immunol        ISSN: 1735-1502            Impact factor:   1.464


  16 in total

1.  Health-related quality of life (HRQL) in immunodeficient adults with selective IgA deficiency compared with age- and gender-matched controls and identification of risk factors for poor HRQL.

Authors:  G H Jörgensen; A Gardulf; M I Sigurdsson; S Arnlaugsson; L Hammarström; B R Ludviksson
Journal:  Qual Life Res       Date:  2014-03       Impact factor: 4.147

2.  Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry.

Authors:  Asghar Aghamohammadi; Payam Mohammadinejad; Hassan Abolhassani; Babak Mirminachi; Masoud Movahedi; Mohammad Gharagozlou; Nima Parvaneh; Vaheid Zeiaee; Bahram Mirsaeed-Ghazi; Zahra Chavoushzadeh; Alireza Mahdaviani; Mahboubeh Mansouri; Sedigheh Yousefzadegan; Bahareh Sharifi; Fariborz Zandieh; Ehsan Hedayat; Ali Nadjafi; Roya Sherkat; Behzad Shakerian; Mahnaz Sadeghi-Shabestari; Reza Farid Hosseini; Farahzad Jabbari-Azad; Hamid Ahanchian; Fatemeh Behmanesh; Mohammadreza Zandkarimi; Afshin Shirkani; Taher Cheraghi; Abbas Fayezi; Iraj Mohammadzadeh; Reza Amin; Soheila Aleyasin; Mojgan Moghtaderi; Javad Ghaffari; Saba Arshi; Naser Javahertrash; Mohammad Nabavi; Mohammad Hassan Bemanian; Alireza Shafiei; Najmedin Kalantari; Akefeh Ahmadiafshar; Hossein Ali Khazaei; Lida Atarod; Nima Rezaei
Journal:  J Clin Immunol       Date:  2014-05       Impact factor: 8.317

Review 3.  Life with a Primary Immune Deficiency: a Systematic Synthesis of the Literature and Proposed Research Agenda.

Authors:  Morgan N Similuk; Angela Wang; Michael J Lenardo; Lori H Erby
Journal:  J Clin Immunol       Date:  2016-02-12       Impact factor: 8.317

4.  Quality of Life, Treatment Beliefs, and Treatment Satisfaction in Children Treated for Primary Immunodeficiency with SCIg.

Authors:  Serge Sultan; Émélie Rondeau; Marie-Claude Levasseur; Renée Dicaire; Hélène Decaluwe; Élie Haddad
Journal:  J Clin Immunol       Date:  2017-06-08       Impact factor: 8.317

5.  Human normal immunoglobulin in the treatment of primary immunodeficiency diseases.

Authors:  Philip Wood
Journal:  Ther Clin Risk Manag       Date:  2012-04-02       Impact factor: 2.423

Review 6.  Health-related quality of life in patients with primary immunodeficiency disease.

Authors:  Fonda Jiang; Troy R Torgerson; Andrew G Ayars
Journal:  Allergy Asthma Clin Immunol       Date:  2015-09-29       Impact factor: 3.406

7.  Differences in Patient Demographics and Healthcare Costs of Patients with PIDD Receiving Intravenous or Subcutaneous Immunoglobulin Therapies in the United States.

Authors:  Michael C Runken; Joshua M Noone; Christopher M Blanchette; Emily Zacherle; Reuben Howden
Journal:  Am Health Drug Benefits       Date:  2019-10

8.  Attentiveness of pediatricians to primary immunodeficiency disorders.

Authors:  Suleiman Al-Hammadi; Eiman Al-Reyami; Sareea Al-Remeithi; Khawla Al-Zaabi; Rola Al-Zir; Heba Al-Sagban; Taoufik Zoubaidi; Abdul-Kader Souid
Journal:  BMC Res Notes       Date:  2012-07-31

9.  Health-Related Quality of Life and Health Resource Utilization in Patients with Primary Immunodeficiency Disease Prior to and Following 12 Months of Immunoglobulin G Treatment.

Authors:  John Routes; Beatriz Tavares Costa-Carvalho; Bodo Grimbacher; Kenneth Paris; Hans D Ochs; Alexandra Filipovich; Mary Hintermeyer; Karina Mescouto de Melo; Sarita Workman; Diane Ito; Xiaolan Ye; Patrick Bonnet; Josephine Li-McLeod
Journal:  J Clin Immunol       Date:  2016-04-18       Impact factor: 8.317

10.  Respiratory Health and Related Quality of Life in Patients with Congenital Agammaglobulinemia in the Northern Region of the UK.

Authors:  Branwen A Bryan; Alex Battersby; Benjamin Martin James Shillitoe; Dawn Barge; Helen Bourne; Terry Flood; Andrew J Cant; Catherine Stroud; Andrew R Gennery
Journal:  J Clin Immunol       Date:  2016-04-18       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.